Drug intelligence / Profile preview

ST-6904

Development stage: Preclinical
Lead developer: Beijing Scitech-Mq Pharmaceuticals
Modality: Small Molecules

Overview

ST-6904 is a small molecule therapeutic candidate currently in preclinical development by Beijing Scitech-Mq Pharmaceuticals. It is being investigated for the treatment of hematological malignancies, including various forms of leukemia. While the drug is identified as a targeted small molecule, its specific biological target and exact mechanism of action have not yet been disclosed by the developer. It represents part of the company's oncology pipeline focused on addressing blood-based cancers.

Beyond the preview

Go deeper on ST-6904.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ST-6904.

Explore the full profile